For example, galectin-9 on glioblastoma-derived EVs binds TIM-3 receptor on DCs, which inhibits DC antigen presentation and suppresses T cell-mediated anti-tumor immune responses [172, 173]. This evidence concerns the gene LGALS9 and neoplasm.